Singapore, Feb 05, 2010: China Biologic Products, a leading plasma-based biopharmaceutical company in China, announced that, effective February 4, 2010, the company has appointed Dr. Xiangmin Cui, to serve as an independent member of its board of directors, as the Chairman of the company's Compensation Committee, and as a member on the company's Audit Committee and Nominating Committee.

 

Dr. Cui is a Principal at Bay City Capital LLC (Bay City), a venture capital firm managing approximately $1.5 billion of capital invested across various healthcare sectors. Prior to joining Bay City, in 2006, Dr. Cui was Director of Strategic Investment Planning for Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that have been approved by the U.S. Food and Drug Administration.

 

Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals, a U.S. biotech company, and Hucon Biopharmaceuticals, a China pharmaceutical company. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003 to 2005, respectively. In these positions, he led the efforts to evaluate and acquire several key technologies in the fields of oncology, infectious and inflammatory diseases. Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America. He received his Ph.D. in Cancer Biology from Stanford University, and his B.S. in Molecular Biology from Peking University.

 

Dr. Cui will fill in the vacancy left by Dr. Gan's resignation on January 8, 2010, to dedicate more time to her other professional activities.